AACR 2020: Selaxib reduces the incidence of sorafenib-related hand-foot syndrome in liver cancer patients
-
Last Update: 2020-07-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
A study presented at the 2020 annual meeting of the American Association for Cancer Research (AACR) showed that seloxib reduces the incidence of sorafeny-related hand and foot syndrome in patients with advanced hepatocellular carcinoma (HCC)Dr Jiancong Chen, of Sun Yat-sen University's Affiliated First Hospital, said: "Skin toxicity, especially hand and foot syndrome, is one of the most common adverse events caused by Sorafenib, leading to interruptions or failures of treatmentThis study shows that seloxien can reduce sorafenib-related skin toxicity."In the study, the researchers randomly divided 166 patients with advanced HCC into sorafenib and seratin combined with sorafenibAlthough patients in the combined treatment group were younger (51.3 to 11.7 years vs57.4 x 11.1 years), the baseline characteristics of the patients in both groups were comparableThe incidence rate of level 2 hand and foot syndrome was 29.3% in the combined treatment group, while the rate was as high as 63.8% in the sorafenib group (P-0.008)patients in the combined treatment group did not experience hair loss of 2 or greater, and 5 (8.6%) experienced hair loss of more than 1 level3 patients in the combined treatment group (5.2%) developed a rash of magnitude 1 or greater, while 16 patients in the single drug treatment group (27.6%) developed a rash of magnitude 1 or greater
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
